ArticleCardiology research2025
Progression of Atherosclerosis and Hypothesis on the Relationship Between Microvascular Dysfunction, Cardiovascular Risk, and Cancer.
Article in Cardiology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The extent of atherosclerosis in healthy men and women was measured using ultrasound in the carotid artery and whether the progression could be predicted using the classic risk factors was investigated. A hypothesis was also formulated as to how microvascular dysfunction and atherosclerosis, on the one hand, and cardiovascular disease and cancer, on the other hand, might be related. To describe the relationship between atherosclerosis and cancer, the classic risk factors and plaque burden were compared. Methods: From 2009 to 2024, 10,597 subjects (44% women) aged 20 - 65 years without signs of cardiovascular disease were examined using ultrasound of the carotid artery. The sum of all plaque areas (total plaque area (TPA)) and the maximum plaque thickness were measured. Follow-up examinations were carried out on 4,520 subjects (42% women) aged 40 - 65 years. In 2,397 men without cancer or cardiovascular events during follow-up, the classic risk factors and plaque burden were compared between 55 men who had a solid tumor and 188 men who had a cardiovascular event, and whether patients with cancer and a cardiovascular event exhibited different risk profiles was examined. Results: In the age group of 35 - 65 years, 12% of men and 4.2% of women had advanced atherosclerosis (types III and IVb). In the age group of 40 - 65 years, 2,592 men and 1,928 women were followed up. Low to moderate atherosclerosis was present in 2,052 (79.2%) men and 1,761 (91.3%) women. Advanced atherosclerosis developed in 139 (6.8%) men and 39 (2.2%) women, which could not be predicted by the classical risk factors (P > 0.05). The mean follow-up time was 73 months (6.1 years) for men and 75 months (6.3 years) for women. Patients without cancer or cardiovascular disease have lower risk factors and lower plaque burden compared to men with cancer or cardiovascular events. Patients with cancer have very similar high-risk factors and high plaque burden compared to patients with cardiovascular disease. Conclusion: By measuring the plaque burden on the carotid artery, a good risk stratification can be achieved in every age group. A follow-up examination every 3 - 5 years is advisable, as a rapid progression of the disease cannot be predicted taking into account the classic risk factors. Early treatment of advanced atherosclerosis improves the prognosis for cardiovascular diseases and possibly also for certain types of cancer. Patients with cancer and cardiovascular events show a similar risk profile and plaque burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.